Northwest Territories, Canada announces biosimilars switching policy

Biosimilars/General | Posted 04/02/2022 post-comment0 Post your comment

The Northwest Territories (NWT) has become the fifth jurisdiction in Canada to implement a biosimilars switching policy. The policy begins from 21 December 2021 and includes 10 biologicals.

Switching mAb Pfizer V18K30

Canada is leading the way in biosimilar policy, with several provinces initiating switching policies to increase biosimilar use, including British Columbia [1], Alberta [2], Ontario [3], and Quebec [4].

NWT, a territory with a population of around 45,000 people, has now become the fifth Canadian jurisdiction – and the first territorial government – to announce a biosimilars switching policy.

From 21 December 2021, NWT residents will have a six-month period to switch from originator biologicals to a biosimilar version. After this time (20 June 2022), coverage under the Extended Health Benefit and Métis Health Benefit Program will be prioritized to biosimilar drugs only, unless an Exception Request is approved for medical reasons.

The programme includes 10 biologicals for a range of health conditions including arthritis, diabetes and inflammatory bowel disease, see Table 1.

Table 1: List of originator biologicals their biosimilar versions included under the NWT biosimilar switching policy
Active ingredient Originator biological Biosimilar Indications
Adalimumab Humira® Amgevita®
Hadlima®
Hulio®
Hyrimoz®
Idacio®
Ankylosing spondylitis
Crohn’s disease
Hidradenitis suppurativa
Plaque psoriasis
Polyarticular juvenile idiopathic arthritis
Psoriatic arthritis
Rheumatoid arthritis
Ulcerative colitis
Non-infectious uveitis
Enoxaparin Lovenox® Inclunox®
Noromby®
Redesca®
Thromboembolic disorders
Etanercept Enbrel® Brenzys®
Erelzi®
Ankylosing spondylitis
Plaque psoriasis
Psoriatic arthritis
Polyarticular juvenile idiopathic arthritis
Rheumatoid arthritis
Infliximab Remicade® Inflectra®
Renflexis®
Avsola®
Ankylosing spondylitis
Plaque psoriasis
Psoriatic arthritis
Rheumatoid arthritis
Crohn’s disease
Ulcerative colitis
Insulin glargine Lantus® Basaglar® Diabetes
Insulin lispro Humalog® Admelog® Diabetes
Insulin aspart NovoRapid® Trurapi® Diabetes
Filgrastim Neupogen® Grastofil®
Nivestym®
Neutropenia
Pegfilgrastim Neulasta® Lapelga®
Fulphila®
Nyvepria®
Ziextenzo®
Neutropenia
Rituximab Rituxan® Truxima®
Riximyo®
Ruxience®
Riabni®
Rheumatoid arthritis
Vasculitis
Autoimmune diseases
Glatiramer Copaxone® Glatect® Multiple sclerosis

 

The NWT Government hopes the initiative will optimize the use of public resources and reduce spending. Supplementary health benefit programme spending on biological drugs in the Territories increased by 17.6% between 2020 and 2021, reaching CA$2.8 million.

Jim Keon, President of Biosimilars Canada – the association representing biosimilars manufacturers in the country – congratulated the NWT Government on implementing a switching policy. He said: ‘Biosimilars Canada and its member companies look forward to working with the Government of the Northwest Territories to ensure the successful implementation of its biosimilars switching policy’.

Adding: ‘It is time for all provincial and territorial governments to follow the lead of the Northwest Territories and four provinces in bringing the benefits of biosimilar switching programs to their patients, healthcare providers and taxpayers’.

Related articles
British Columbia expands biosimilar switching programme to include insulin

Canadian provinces expand their use of biosimilars

British Columbia adds adalimumab to biosimilar switching programme

LATIN AMERICAN FORUM

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View last week’s headline article: Diferencias en inmunogenicidad, farmacovigilancia y documentos legales en productos biológicos en América Latina

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de la semana pasada: Diferencias en inmunogenicidad, farmacovigilancia y documentos legales en productos biológicos en América Latina

iExplore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

  

References
1. GaBI Online - Generics and Biosimilars Initiative. Canada’s British Columbia to switch patients to biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Feb 4]. Available from: www.gabionline.net/policies-legislation/Canada-s-British-Columbia-to-switch-patients-to-biosimilars
2. GaBI Online - Generics and Biosimilars Initiative. Alberta Biosimilars Initiative: switching policy updates in Canada [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Feb 4]. Available from: www.gabionline.net/biosimilars/general/Alberta-Biosimilars-Initiative-switching-policy-updates-in-Canada
3. GaBI Online - Generics and Biosimilars Initiative. Ontario becomes third Canadian province to switch patients to biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Feb 4]. Available from: www.gabionline.net/biosimilars/general/Ontario-becomes-third-Canadian-province-to-switch-patients-to-biosimilars
4. GaBI Online - Generics and Biosimilars Initiative. Quebec announces biosimilar switching policy [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Feb 4]. Available from: www.gabionline.net/biosimilars/general/Quebec-announces-biosimilar-switching-policy

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.

Source: The Government of Northwest Territories

comment icon Comments (0)
Post your comment
Related content
Biosimilars of pembrolizumab
Cancer image015
Biosimilars/General Posted 14/10/2022
EMA calls for biosimilar interchangeability across the EU
01 AA007239
Biosimilars/General Posted 23/09/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010